News
IGC
0.4000
-2.70%
-0.0111
Anti-Legalization Group Smart Approaches For Marijuana Bands Together With Law Enforcement, Parent Groups And Others To Ask The Senate Not To Pass The SAFE Banking Act
Benzinga · 11/22 14:27
New York Gives First Pot Licenses; 8 Nonprofits, 29 Individuals
Benzinga · 11/21 15:32
'Marijuana Dispensaries Near You, First NY Pot Retail Licenses Go Out Next Week'
Benzinga · 11/18 13:26
'House Democrats And Republicans Publish 'Joint Memo' On Marijuana Ahead Of Congressional Legalization Hearing' - Marijuana Moment
Benzinga · 11/14 17:44
'Booker Says Marijuana Reform Can Pass 'Now' During Lame Duck Or 'Many Years From Now' After GOP Takes House Control' - Marijuana Moment
Benzinga · 11/14 16:19
'Minnesota Governor Says Marijuana Legalization Will Be 'One Of The First' Bills To Pass With Democrats In Control: The governor has already invited former Gov. Jesse Ventura to the future signing ceremony.' - Marijuana Moment
Benzinga · 11/10 22:10
'Congress Will Hold A Marijuana Hearing One Week After Five States Vote On Legalization Ballot Measure' -Marijuana Moment Report
Benzinga · 11/08 16:56
"Biden Promotes His Marijuana Pardons Days Before The Election, But Reiterates Relief Is 'Just For Possession'" - Marijuana Moment
Benzinga · 11/04 16:00
'Maryland Marijuana Legalization Campaign Targets Young Voters In New Ad To Boost Election Turnout' -Marijuana Moment Report
Benzinga · 11/03 15:56
IGC Q2 2023 Revenue Grows 261%, THC Based Drug For Alzheimer's Entering Phase 2 Trials
Benzinga · 11/02 12:19
BRIEF-Igc Reports Results For Second Fiscal Quarter Ended Sept 30
Reuters · 11/01 21:26
India Globalization Capital GAAP EPS of -$0.05, revenue of $0.2M
Seekingalpha · 11/01 21:14
IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022
POTOMAC, Md., November 01, 2022--India Globalization Capital, Inc. (NYSE American: IGC) ("IGC" or the "Company") today reported its second fiscal quarter 2023 financial results.
Business Wire · 11/01 20:30
-- Earnings Flash (IGC) INDIA GLOBALIZATION CAPITAL Posts Q2 Revenue $202,000
-- Earnings Flash (IGC) INDIA GLOBALIZATION CAPITAL Posts Q2 Revenue $202,000
MT Newswires · 11/01 16:43
Cannabis Stocks Moved Lower Earlier; Traders Circulate Opinion Piece From Faz.Net Titled 'Huge consequences for public health'
Benzinga · 11/01 12:55
'Schumer Says Congress Is 'Very Close' To Passing Marijuana Banking And Expungements Bill After Work With 'A Bunch Of Republicans': "We may be able to get something done rather soon."' - Marijuana Moment
Benzinga · 10/31 15:24
'New Jersey Lawmakers Approve Bill To Let Marijuana Businesses Claim State Tax Deductions As Partial 280e Workaround' - Marijuana Moment
Benzinga · 10/28 15:51
'Nevada Judge Orders Board Of Pharmacy To Remove Marijuana From Schedule I Under Agency's 'Unconstitutional' Code' - MarijuanaMoment
Benzinga · 10/27 15:48
'NBA Won't Test Players For Marijuana For Third Season In A Row, Report Says' - Marijuana Moment
NBA Won't Test Players For Marijuana For Third Season In A Row, Report Says - Marijuana Moment For the third season in a row, the National Basketball Association (NBA) will reportedly not be randomly testing players
Benzinga · 10/19 12:30
'White House Drug Czar Says Marijuana 'Clearly' Has Medical Value And Scheduling Review Must Follow Science' - Marijuana Moment
White House Drug Czar Says Marijuana 'Clearly' Has Medical Value And Scheduling Review Must Follow Science - Marijuana Moment The White House drug czar says that it’s key to ensure that any decision
Benzinga · 10/18 15:32
More
Webull provides a variety of real-time IGC stock news. You can receive the latest news about India Glbl Cptl through multiple platforms. This information may help you make smarter investment decisions.
About IGC
India Globalization Capital, Inc. is engaged in infrastructure and life sciences businesses. The Company's segments include Life Sciences and Infrastructure. The Life Sciences segment operates primarily through wholly owned subsidiaries, including IGC Pharma LLC, a clinical-stage biopharmaceutical company based in Maryland. The purpose of IGC Pharma LLC is to treat Alzheimer's patients and alleviate caregiver burden. The Life Sciences segment also includes the development of over-the-counter personal care products, operated by certain of the Company's subsidiaries under various brands. The Infrastructure segment involves the execution of construction contracts and the rental of heavy construction equipment. It has two main investigational drug assets, which are IGC-AD1 and TGR-63. Its lead therapeutic candidate, IGC-AD1 is in Phase II trials for treating agitation in dementia from Alzheimer's and TGR-63, an enzyme inhibitor to reduce neurotoxicity in Alzheimer's cell lines.